Current Approaches to Managing Patients With Obesity: Considering Weight Loss, Comorbidities, Pharmacotherapy, and Complications
Release Date: December 17, 2021
Last Reviewed: December 15, 2021
Expiration Date: December 17, 2022
Time to Complete Activity: 1.0 hour
Robert F. Kushner, MD (Chair)
Professor of Medicine and Medical Education
Northwestern University Feinberg School of Medicine
Director, Center for Lifestyle Medicine
Angela Fitch, MD, FACP, FOMA
Instructor of Medicine
Harvard Medical School
Massachusetts General Hospital Weight Center
W. Timothy Garvey, MD
Director, Diabetes Research Center
University of Alabama at Birmingham
Craig Primack, MD, FACP, FAAO, FOMA
Scottsdale Weight Loss Center
This activity is provided by Paradigm Medical Communications, LLC.
In partnership with the Obesity Medicine Association (OMA) and Obesity Action Coalition (OAC).
Disclosure of Financial Support
This activity is supported by an educational grant from Novo Nordisk Inc.
This activity has been designed for clinicians interested in the management of patients with obesity. Specialties include primary care providers, cardiologists, endocrinologists, obstetricians/gynecologists, and rheumatologists.
Statement of Need
Obesity continues to become more prevalent in the United States, and with it, patients’ health and quality of life are diminished by increased incidence of cardiovascular disease, cometabolic conditions, some cancers, and mood disorders. The majority of clinicians are uncertain addressing obesity and weight loss for and with their patients out of fear of alienating the patient. Few clinicians are up to date on recent data supporting the use of glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) for weight loss in terms of the extraglycemic effects that induce satiety and reduce effects of adiposopathy, resulting in weight loss and reduced obesity-related morbidity and mortality. Clinicians seek education to help foster weight loss to aid patients in achieving their health goals.
Upon completion of this activity, participants should be able to:
- Discuss the parameters of the diagnosis of obesity and the impact on patient health
- Summarize the efficacy of GLP-1 RAs for weight loss and effects on comorbid conditions and related complications
- Select evidence-based, guideline-aligned treatment for patients with obesity and comorbid conditions and related complications
Defining Obesity and Its Effects
Pharmacologic Treatment of Obesity
Pathways to Effective Patient Communication
Physician Accreditation Statement
Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician Credit Designation Statement
Paradigm Medical Communications, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Participation
To receive a CME certificate of participation, you should:
- Follow instructions to register or log in with your professional information and complete the preactivity assessment
- View the online activity in its entirety
- Complete and submit the online posttest and evaluation. You must answer 70% of the posttest questions correctly to earn credit. You will have unlimited opportunities to successfully complete the posttest
A certificate of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation.
For questions regarding CME credit, contact the Paradigm CME Department at (845) 398-5949 or firstname.lastname@example.org.
There is no fee required for participation in this activity.
This certified CME activity is designed using HTML5 web components. As you navigate the video using the supplied controls, the slides will sync to the speaker.
Supported Browsers (Desktop/Mobile)
Chrome 45+, Firefox 40+, Edge, Edge Chromium, Safari 8+, Opera 31+
This activity may contain PDF documents. Most current browsers support viewing of PDFs natively, but you may also download a free version of Adobe Acrobat Reader here: http://get.adobe.com/reader
Technical Support: If you have any technical problems or playback issues, email us at email@example.com.
In accordance with ACCME requirements on disclosure, faculty and contributors are asked to disclose any financial relationships occurring over the past 24 months with ineligible companies whose products or services are associated with the area of medicine featured in the activity. These relationships are described below. Any potential conflicts of interest have been mitigated.
Angela Fitch, MD, FACP, FOMA
W. Timothy Garvey, MD
Research Funding: Eli Lilly and Company; Epitomee; Novo Nordisk, Inc.; Pfizer Inc (expired)
Robert F. Kushner, MD
Advisor: Novo Nordisk, Inc.; Pfizer Inc
Research Funding: Epitomee
Craig Primack, MD,, FACP, FAAO, FOMA
Advisor: Gelesis; Phenomix Sciences
Speaker’s Bureau: Currax Pharmaceuticals LLC
Paradigm Medical Communications, LLC staff members have no relevant financial relationships with ineligible companies to disclose.
Obesity Medicine Association staff member has no relevant financial relationships with ineligible companies to disclose.
Independent peer reviewer has no relevant financial relationships with ineligible companies to disclose.
Resolution of Conflict of Interest
Paradigm Medical Communications, LLC has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair and balanced, independent, and aligned with the public interest. Conflicts, if any, are mitigated through one or more processes. All CME content in this activity was independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.
This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.
As an ACCME-accredited provider, Paradigm Medical Communications, LLC’s activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. In this activity, the trade names for neuromodulators and soft tissue fillers are used for clarity. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.
The materials provided for this activity are for informational purposes only, and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC. Paradigm Medical Communications, LLC accepts no liability for the content referenced in this activity.
Paradigm Medical Communications, LLC or hosted contracted partner is committed to protecting the privacy of those who participate in the activities located at www.paradigmmc.com (herein referred to as “website”). The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.
Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.
Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC to continuously improve the learning experience.
Paradigm Medical Communications, LLC does not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC staff members review individual test results to the extent necessary to record and track participants’ credits.
If you have any questions or comments, please email us at firstname.lastname@example.org.
© 2021 Paradigm Medical Communications, LLC except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.